No, CellCept (mycophenolate mofetil) causes neutropenia, not neutrophilic leukocytosis
CellCept is associated with decreased white blood cell counts, specifically neutropenia, not elevated neutrophil counts. This is a well-established adverse effect documented in FDA labeling and multiple clinical guidelines.
Hematologic Effects of CellCept
Neutropenia (Decreased Neutrophils)
The FDA drug label explicitly warns that severe neutropenia (absolute neutrophil count <0.5 × 10³/µL) developed in up to 2.0% of renal, 2.8% of cardiac, and 3.6% of hepatic transplant patients receiving CellCept 3g daily 1. This bone marrow suppression is dose-dependent and most commonly occurs between 31-180 days post-transplant 1.
Multiple guidelines confirm this effect:
- The 2019 American Society of Hematology guidelines state that "significant side effects include neutropenia, anemia, and viral infections" when discussing mycophenolate mofetil 2
- The 2006 transplant guidelines note that "azathioprine and mycophenolate mofetil are myelosuppressive; therefore, anemia caused by these drugs often is associated with leukopenia and/or thrombocytopenia" 3
- The 2020 NCCN guidelines report neutropenia as a recognized toxicity requiring drug discontinuation in some patients 4
Clinical Evidence
A 2015 study in SLE patients found that mycophenolate mofetil does not worsen leukopenia—in fact, patients with baseline WBC <3000/mm³ showed statistically significant increases in WBC after starting the drug (2.57 vs. 5.13, P=0.0047) 5. This demonstrates that while MMF can cause neutropenia in some patients, it does not cause neutrophilic leukocytosis.
Mechanism of Action
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, blocking purine synthesis primarily in lymphocytes, thereby inhibiting DNA synthesis of T and B cells 2. This antiproliferative mechanism affects rapidly dividing cells, including bone marrow precursors, leading to decreased production of white blood cells, not increased production 6.
Monitoring Requirements
Patients receiving CellCept should be monitored for neutropenia with regular blood counts 1. If neutropenia develops (ANC <1.3 × 10³/µL), dosing should be interrupted or reduced 1. The FDA label specifically instructs patients to "report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression" 1.
Other Hematologic Effects
Beyond neutropenia, CellCept causes:
- Anemia (decreased red blood cells) 3, 1
- Thrombocytopenia (decreased platelets) 3, 1
- Pure red cell aplasia in rare cases 2, 1
Clinical Pitfall
If you observe neutrophilic leukocytosis in a patient taking CellCept, look for alternative causes such as infection, inflammation, or other medications. The leukocytosis is not caused by CellCept itself. In fact, one case report documented neutrophilic leukocytosis (3.7%) in the context of ipilimumab-induced nephritis treated with mycophenolate mofetil, but this was attributed to the underlying inflammatory condition, not the MMF 7.